BRAINSTORM CELL THERAPEUTICS INC. 10-K Cybersecurity GRC - 2024-04-01

Page last updated on July 16, 2024

BRAINSTORM CELL THERAPEUTICS INC. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-04-01 09:16:01 EDT.

Filings

10-K filed on 2024-04-01

BRAINSTORM CELL THERAPEUTICS INC. filed a 10-K at 2024-04-01 09:16:01 EDT
Accession Number: 0001410578-24-000385

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C. CYBERSECURITY SECTION Cybersecurity Risk Management and Strategy In recognition of the evolving cybersecurity threat landscape, we acknowledge the increasing sophistication and frequency of cybersecurity incidents, including unauthorized access to critical health information and other personal data. Although we cannot completely protect against the possibility of a cybersecurity incident occurring, we take proactive measures designed to help prevent and mitigate risks from cybersecurity threats, including measures implemented by our third-party managed services provider. We are dedicated to investing in our cybersecurity infrastructure in an effort to safeguard our data confidentiality, integrity, and availability, and uphold the trust of our stakeholders. As part of our cybersecurity procedures, we leverage a number of security tools, including but not limited to email filters, firewalls, and antivirus protection. We also test certain of our applications for vulnerabilities. In an effort to raise cybersecurity awareness, we work with an external partner to send email notices to our employees regarding cybersecurity best practices. We work to mitigate risks from cybersecurity threats stemming from third-party vendors by providing them with access only to systems that they need to provide services to us. We are currently developing processes to enhance our vendor management processes. We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. However, like other companies in our industry, we and our third-party vendors have from time to time experienced threats that could affect our information or systems. Cybersecurity Governance Our Chief Business Officer (“CBO”) is responsible for day-to-day management of our cybersecurity strategy. Our CBO manages the Company’s response to risks from cybersecurity threats, and works with our managed services provider to implement cybersecurity controls. The Audit Committee of our Board of Directors is primarily responsible for overseeing the Company’s compliance and risk management obligations.


Company Information

NameBRAINSTORM CELL THERAPEUTICS INC.
CIK0001137883
SIC DescriptionBiological Products, (No Diagnostic Substances)
TickerBCLI - Nasdaq
Website
CategoryNon-accelerated filer
Smaller reporting company
Fiscal Year EndDecember 30